Gimatecan

Drug Profile

Gimatecan

Alternative Names: CPT-184; LBQ 707; NVP-LBQ707; ST-1481

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Istituto Nazionale per lo Studio e la Cura dei Tumori; sigma-tau SpA
  • Developer Lees Pharmaceutical Holdings; Novartis; sigma-tau SpA
  • Class Antineoplastics; Benzylisoquinolines; Camptothecins; Heterocyclic compounds with 4 or more rings; Imines; Small molecules
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Discontinued Glioma; Myelodysplastic syndromes; Solid tumours

Most Recent Events

  • 04 Feb 2016 No development reported - Phase-II for Fallopian tube cancer (Recurrent) in China (PO)
  • 04 Feb 2016 No development reported - Phase-II for Ovarian cancer (Recurrent) in China (PO)
  • 04 Feb 2016 No development reported - Phase-II for Peritoneal cancer (Recurrent) in China (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top